Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 5:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Arm A Clear all
Terminated Phase 2 Interventional Results available

Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

NCT00107315
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, capecitabine
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
70 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Sep 14, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional

A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair

NCT06529835
View directory record Official record
Conditions
Peripheral Nerve Injuries
Interventions
NeuroSpan Bridge, NeuroGen Nerve Guide, Nerve Autograft
Device
Lead sponsor
Auxilium Biotechnologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

NCT03619876
View directory record Official record
Conditions
Rheumatoid Arthritis, Myocardial Inflammation
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economic Strategies to Improve PRO Adherence

NCT06013176
View directory record Official record
Conditions
Cancer
Interventions
Encounter-based PRO monitoring, Remote PRO monitoring
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Plainsboro, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Caregiver Self-Management of Stress

NCT04337021
View directory record Official record
Conditions
Caregiver Distress, Job Stress
Interventions
Caregiver SOS
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

NCT01482052
View directory record Official record
Conditions
Meningococcal Meningitis, Meningococcal Infections
Interventions
meningococcal meningitis conjugate vaccine, quadrivalent
Biological
Lead sponsor
JN-International Medical Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building Resiliency and Increasing Community Hope

NCT01698047
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Resiliency Class, Case Management
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 14, 2026, 5:34 PM EDT
Terminated Phase 2 Interventional Results available

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

NCT00387426
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia
Interventions
sunitinib malate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 14, 2026, 5:34 PM EDT
Terminated Not applicable Interventional Results available

Auris Robotic Endoscopy System for Bronchoscopy

NCT03497026
View directory record Official record
Conditions
Lung Cancer
Interventions
Robotic Bronchoscopy Platform
Device
Lead sponsor
Auris Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00354835
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
196
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 14, 2026, 5:34 PM EDT
Active, not recruiting Phase 1 Interventional

Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence

NCT05616208
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Bioengineered Internal Anal Sphincter
Biological
Lead sponsor
Cellf Bio LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 14, 2026, 5:34 PM EDT
Active, not recruiting Phase 1 Interventional

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

NCT04731376
View directory record Official record
Conditions
Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate
Other · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976
View directory record Official record
Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01776840
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab, Ibrutinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
44
States / cities
Tucson, Arizona • Burbank, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 14, 2026, 5:34 PM EDT
Withdrawn Not applicable Interventional

Invasive Brain-Computer Interfaces for Attention

NCT06940089
View directory record Official record
Conditions
Epilepsy in Children, Epilepsy
Interventions
Attention Intervention using a customized BCI decoder, Attention Intervention without using a customized BCI decoder
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Not applicable Interventional

Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery

NCT01416168
View directory record Official record
Conditions
Colorectal Cancer
Interventions
McCorkle Model Intervention
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

NCT01229150
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
AZD6244, Erlotinib, AZD6244 + Erlotinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Davis, California • Los Angeles, California • South Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 14, 2026, 5:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sustaining and Improving Clinicians' Use of Evidence-Based Psychotherapy (EBP) for PTSD

NCT02449421
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Quality Improvement Learning Community, Fidelity-oriented Learning Community
Behavioral
Lead sponsor
Toronto Metropolitan University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
2
States / cities
Menlo Park, California • San Antonio, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 14, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kaempferol Absorption and Pharmacokinetics Evaluation

NCT07322406
View directory record Official record
Conditions
No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions
Kaempferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Measuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos

NCT07679048
View directory record Official record
Conditions
Distance Viewing, Prolonged Near Viewing
Interventions
Near viewing first, Distant viewing first
Other
Lead sponsor
Rochester Institute of Technology
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 14, 2026, 5:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Monell USDA Taste Test Study

NCT04079855
View directory record Official record
Conditions
Healthy Diet
Interventions
Diet composition 1, Diet composition 2, Diet composition 3
Other
Lead sponsor
David Baer
Federal
Eligibility
25 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 14, 2026, 5:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

NCT04530955
View directory record Official record
Conditions
Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions
Prometra II Programmable Pump - Flowonix Medical
Device
Lead sponsor
Culicchia Neurological Clinic
Other
Eligibility
22 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marrero, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 14, 2026, 5:34 PM EDT
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

NCT00324155
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Placebo, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
32
States / cities
Anaheim, California • La Verne, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 14, 2026, 5:34 PM EDT